Sumanta (Monty) Kumar Pal, M.D., F.A.S.C.O., is an internationally recognized leader in kidney cancer.
Dr. Pal entered college at the age of 13 and began medical school at University of California Los Angeles at the age of 17. After completing his residency training at UCLA, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he has remained on faculty since 2009.
Over that span of time, he has published more than 550 PubMed cited articles that have been featured in prominent journals including The Lancet, Cancer Cell and Nature Medicine.
Dr. Pal maintains one of the largest portfolios of clinical trials for kidney cancer on the West Coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at the Beckman Research Institute of City of Hope and urologists in the Department of Surgery. He is well known for his practice-defining work in rare types of kidney cancer (such as papillary kidney cancer) and is a pioneer in techniques to modulate the gut microbiome to enhance the impact of cancer treatment. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for currently incurable diseases. He is the lead investigator on multiple trials, ranging from early phase 1 experiences to late-stage phase 3 studies.
Dr. Pal sits on the editorial board for CA: A Journal for Clinicians and European Urology, and is the host of the City of Hope podcast, “On the Edge of Breakthrough: Voices of Cancer Research.”
Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network and multiple other leading entities in support of his formidable research.
